Emergent BioSolutions EBS
NYSE EBS
$6.10 +0.00 (+0.00%)
As of: Nov 10, 2026 · 12:46 PM EST

Emergent BioSolutions (EBS) Total Current Liabilities (2010 - 2026)

Updated

Emergent BioSolutions' Total Current Liabilities came in at $122 million for Q3 2026, down 10.6% from $136.5 million a year earlier and down 0.7% from the prior quarter.

Analysis

Emergent BioSolutions (EBS) Total Current Liabilities (2010 - 2026) Analysis & Trends

At the end of FY2025, Emergent BioSolutions' Total Current Liabilities was $132.2 million, down 18.6% from FY2024.

  • Total Current Liabilities has declined in each of the last three years, with a five-year compound annual growth rate of -19.2% (FY2020 to FY2025).
  • Going back by year, Total Current Liabilities was $162.4 million in FY2024 (-75.1%), $651.3 million in FY2023 (-47.0%), $1.23 billion in FY2022 (+228.6%) and $374 million in FY2021 (-2.7%).
  • The Q3 2026 figure represents the lowest quarterly Total Current Liabilities since Q1 2025.
  • Year-over-year, Total Current Liabilities increased in 1 of the last eight quarters, with an average decline of 34.6%.
  • The fastest year-over-year change in Total Current Liabilities over five years came in Q1 2023 (growth of 387.8%), and the weakest in Q1 2025 (a decline of 82.2%).
  • Business Quant data shows EBS's Total Current Liabilities at $122.8 million (Q2 2026), $148.7 million (Q1 2026) and $132.2 million (Q4 2025) in the three quarters before Q3 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 47.00 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 55.46 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 43.10 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 28.80 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 31.75 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 31.55 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 23.23 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 12.00 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 31.73 Bn
10 Emergent BioSolutions 310.37 Mn -370.73 Mn 29.20 Mn 122.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 122.00 Mn
Jun 30, 2026 122.80 Mn
Mar 31, 2026 148.70 Mn
Dec 31, 2025 132.20 Mn
Sep 30, 2025 136.50 Mn
Jun 30, 2025 127.10 Mn
Mar 31, 2025 111.90 Mn
Dec 31, 2024 162.40 Mn
Sep 30, 2024 229.90 Mn
Jun 30, 2024 619.70 Mn
Mar 31, 2024 630.20 Mn
Dec 31, 2023 651.30 Mn
Sep 30, 2023 664.00 Mn
Jun 30, 2023 693.20 Mn
Mar 31, 2023 1.22 Bn
Dec 31, 2022 1.23 Bn
Sep 30, 2022 264.40 Mn
Jun 30, 2022 276.70 Mn
Mar 31, 2022 249.20 Mn
Dec 31, 2021 374.00 Mn
API Access

Emergent BioSolutions Total Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-current-liabilities&ticker=EBS&period=max&api_key=YOUR_API_KEY